Related Experiment Videos
Somnambulism (sleepwalking)
Agnes Remulla1, Christian Guilleminault
1Stanford University Sleep Disorders Clinic, Palo Alto, CA 94305, USA.
Expert Opinion on Pharmacotherapy
|October 6, 2004
Summary
Sleepwalking (somnambulism) affects children and adults, with severe cases requiring medication. Treating underlying conditions like sleep apnea is the most effective approach to eliminate sleepwalking episodes.
Area of Science:
- Neurology
- Sleep Medicine
- Parasomnias
Background:
- Sleepwalking, or somnambulism, is a parasomnia characterized by complex behaviors during sleep.
- It affects a significant portion of both children (2-14%) and adults (1.6-2.4%).
- While occasional episodes are benign, recurrent instances pose injury risks, necessitating intervention.
Purpose of the Study:
- To review the management of sleepwalking (somnambulism).
- To highlight pharmacotherapy options for severe cases.
- To emphasize the importance of treating underlying sleep disorders.
Main Methods:
- Review of current literature on somnambulism management.
- Discussion of pharmacologic treatments including benzodiazepines, tricyclic antidepressants, and SSRIs.
- Emphasis on diagnosing and treating associated sleep disorders.
Main Results:
- Pharmacotherapy (e.g., clonazepam) is indicated for recurrent sleepwalking with injury risk.
- Treatment of underlying conditions like obstructive sleep apnea, RLS, and PLMD is highly effective.
- Addressing root causes often resolves somnambulism in pediatric and adult populations.
Conclusions:
- Conservative management is suitable for benign sleepwalking episodes.
- Urgent pharmacotherapy is required for high-risk recurrent sleepwalking.
- Treating underlying sleep disorders represents the optimal strategy for somnambulism resolution.